A61K 40/4526
Corynebacterium or propionibacterium, actinobacteria
Official title: {Corynebacterium or Propionibacterium, Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium or Gardnerella}
A61K40/4526 (Corynebacterium or propionibacterium, actinobacteria) appears on 5 US grants and 12 published applications in this corpus.
Search patents in A61K- Granted patents
- 5
- Published applications
- 12
- Assignees
- 6
- Inventors
- 21
- Latest grant
- 9 Jan 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 3 |
| 2022 | 0 | 1 |
| 2023 | 1 | 0 |
| 2024 | 1 | 2 |
By publication year.
Recent patents
- Oligomeric particle reagents and methods of use thereof9 Jan 2024US 11,866,465 B2Juno Therapeutics, Inc.
- Tetanus toxoid and CCL3 improve DC vaccines27 Jun 2023US 11,684,662 B2Duke University
- Tetanus toxoid and CCL3 improve DC vaccines27 Jul 2021US 11,071,777 B2Duke University
- Tetanus toxoid and CCL3 improve DC vaccines22 May 2018US 9,974,848 B2Duke University
- Generation of human regulatory T cells by bacterial toxins for the treatment of inflammatory disorders24 Feb 2009US 7,494,812 B2University of Southern California
- Personalized immunotherapy using intestinal metabolites27 Jun 2024US 2024/0207403 A1
- Oligomeric particle reagents and methods of use thereof28 Mar 2024US 2024/0101613 A1Juno Therapeutics, Inc.
- Tetanus toxoid and ccl3 improve dc vaccines3 Feb 2022US 2022/0031827 A1Duke University
- Autologous and allogenic macrophages and monocytes for use in therapeutic methods6 May 2021US 2021/0128611 A1Cellular Approaches, Inc.
- Oligomeric particle reagents and methods of use thereof4 Feb 2021US 2021/0032297 A1Juno Therapeutics, Inc.
Most cited
By later US patents
- Tetanus toxoid and CCL3 improve DC vaccines8US 9,974,848 B2Duke University · 2018
- Oligomeric particle reagents and methods of use thereof5US 11,866,465 B2Juno Therapeutics, Inc. · 2024
- Generation of human regulatory T cells by bacterial toxins for the treatment of inflammatory disorders2US 7,494,812 B2University of Southern California · 2009